Text Size: a  |   a 

Report: Cannabis-Derived Sativex Effective & Safe for MS Related Spasticity

October 26, 2015

Spain-based pharmaceutical firm Almirall presented clinical evidence at the ECTRIMS conference earlier this month that supports the efficacy of its Sativex product when it comes to MS treatment.

Sativex is an oromucosal spray that contains balanced amounts of Cannabis Sativa hemp plant, THC and cannabidiol. Sativex is supplied in small vials as a spray. It is meant to be directed underneath the tongue or inside the cheek.

 “Sativex large studies presented today show new supportive evidence in clinical practice on the effectiveness and tolerability of Sativex as the first cannabinoid based treatment for resistant spasticity in all types of MS,” Maria Trojano, MD, Professor of Neurology and Head of the Department of Basic Medical Sciences Neuroscience and Sensory Organs at the University of Bari in Italy said in the press release.

She continued, “Sativex inhibits the anomalous nerve impulses that cause rigidity and muscle spasms providing effective relief in spasticity and associated symptoms with an acceptable tolerability profile. Patients can experience improvement in their MS spasticity related symptoms in a safe way and thereby benefit from an increased quality of life.”
Video of this and the other findings from the 31st ECTRIMS Congress can be accessed here.